Carrimycin

Identification

Name
Carrimycin
Accession Number
DB16476
Description
Not Available
Type
Small Molecule
Groups
Investigational
Synonyms
  • 4''-Isovalerylspiramycin
  • Carrimycin

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action

Carrimycin is used in clinical trials to determine anti-SARS-CoV-2 activity. Its actions involve inhibiting protein synthesis through binding to the ribosome of bacteria.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
K5E0V85NB9
CAS number
Not Available

References

General References
  1. Lima WG, Brito JCM, Overhage J, Nizer WSDC: The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review. Arch Virol. 2020 Aug;165(8):1729-1737. doi: 10.1007/s00705-020-04693-5. Epub 2020 Jun 8. [PubMed:32514689]
  2. Rosa SGV, Santos WC: Clinical trials on drug repositioning for COVID-19 treatment. Rev Panam Salud Publica. 2020 Mar 20;44:e40. doi: 10.26633/RPSP.2020.40. eCollection 2020. [PubMed:32256547]
  3. External Link [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Oral Squamous Cell Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on January 21, 2021 01:43 / Updated on April 07, 2021 09:52